NDAQ Nasdaq Inc

Despite the really tough day for $NDAQ yesterday, we managed to bring to you all some decent options performing better, like $EDHL proposed back on Oct 07, highlighting the consequences of WestPark Capital announcing closing of $8 Million Public Offering. Keep getting ahead of the game with one of our daily market research reports! 👔💼📉📈💎🙌.

$NDAQ NDX It will drop to the 26,500 area. THEN It will reach a new peak at the beginning of the year.

Would start to get weary of chasing $NDAQ as it nears $110 at this resistance trendline.. Daily RSI nearly overbought.

$NDAQ I predict that yesterday was the final day of the Q4 retail shake out. The big players will be taking advantage of many tremendously undervalued stocks from today onwards.

Narragansett Bancorp made its Nasdaq Capital Market debut on Monday under ticker NARA, with shares opening at $10.80, 8% above its $10 IPO price. The listing completes the two-tier mutual holding company reorganization of its subsidiary, BayCoast Bank, establishing a publicly traded ownership structure. The IPO generated gross proceeds through the sale of 9,098,800 shares at $10 each, including 761,760 shares purchased by the bank's Employee Stock Ownership Plan (ESOP). Following the restructuring, parent company Narragansett Financial Corporation retains a controlling stake through 11.638M shares, while another 423,200 shares were donated to the BayCoast Charitable Foundation, bringing total shares outstanding to 21.16M. Piper Sandler served as the offering agent. $NDAQ

Lycia Therapeutics made its Nasdaq debut Friday after upsizing its IPO to raise $317.5 million, signaling strong investor demand for innovative biotechnology platforms targeting high-value immunology and allergy markets. The South San Francisco-based company priced 17.64 million shares at $18 each, the top of its expected range, up from the initially planned 14.7 million shares. Shares opened at $28.55 before retreating to $23.89 by midday, implying a market capitalization of approximately $1.31 billion. Proceeds will primarily fund clinical development of Lycia’s proprietary LYTAC protein-degradation platform, based on research by Nobel laureate Carolyn Bertozzi. Its cataLYTAC technology is designed to repeatedly eliminate disease-causing extracellular proteins. Key programs include LCA-0061, an IgE-targeting degrader for food allergies, and LCA-0321, designed to selectively remove pathogenic autoantibodies associated with Graves’ disease. $NDAQ

$NDAQ — Last quarter every IPO verb was superlative: "historic," "largest in history." This quarter: a "modest softening in the IPO environment in recent weeks." Win rate held at 79% (74% YTD), pipeline still "robust." Reprioritized: → Reg NMS/Order Protection Rule debate ran several paragraphs last call, drew no real follow-up this time → Market Services growth decelerated from 11% to 2% ($340M to $309M) on largely the same structural explanations What delivered: → 38% of ARR now runs through SaaS with a 1.5x cloud-migration ACV uplift → Enterprise financial-crime signings hit 12 YTD (already past all of 2025) → Index growth accelerated to 39% with ETP AUM above $1.1T #TheGapReport

$NDAQ Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $1.04 up 18.18% YoY • Reported revenue of $2.39B up 81.98% YoY • Nasdaq updated its 2026 non-GAAP operating expense guidance to a range of $2.55B to $2.58B and maintained 2026 non-GAAP tax rate guidance in the range of 22.5% to 24.5%.

$NDAQ Q3 net revenue came in at 1.5 billion dollars, up 13%, and the mix keeps shifting toward recurring revenue. Index revenue jumped 39% on 49 billion dollars of net inflows in the quarter alone, ARR hit a record 3.4 billion dollars, and non-GAAP EPS of 1.04 dollars edged past the 1.02 dollar consensus.

$NDAQ Follow-up: Nasdaq guides 2026 non-GAAP opex to $2.550B–$2.580B. 🏢 Nasdaq runs exchanges, index and fintech arms, worth about $53.73B at $96.12 (16:00 ET, Oct 21, 2026); its LeveL Markets ATS buy closed early Q4 ⚠️ Non-GAAP opex was $638M in Q3, up 9% from $583M; with $1,887M spent through Sept 30, the guide implies $663M–$693M in Q4 📈 Q3 net revenue rose 13% to $1,481M and non-GAAP EPS 18% to $1.04; GAAP EPS of $0.96 got help from a legal settlement 📅 Next: Nasdaq Stock Market on track for 23/5 trading from December 6, 2026 Source: GlobeNewswire release, Oct 22, 2026

NASDAQ $NDAQ Q3’26 EARNINGS HIGHLIGHTS - Revenue: $1.48B (Est. $1.47B) 🟢; +13% YoY - Adj. EPS: $1.04 (Est. $1.02) 🟢; +18% YoY - Adj. Operating Income: $843M (Est. $828M) 🟢 - ARR: $3.37B; +12% YoY

City Therapeutics made a strong Nasdaq debut on Friday, surging approximately 28% after raising $200 million in an upsized IPO. The Cambridge, Massachusetts-based biotechnology company sold 11.11 million shares at $18 each, expanding the offering from an initial 9.72 million shares. Trading opened at $23, valuing the company at approximately $1.19 billion based on total shares outstanding. The IPO attracted support from prominent healthcare investors, including Arch Venture Partners and Fidelity Management & Research, highlighting strong institutional demand for early-stage RNA interference (RNAi) developers. Underwriters also received a 30-day option to purchase up to an additional 1.67 million shares at the IPO price. City Therapeutics plans to use the proceeds to advance its proprietary RNAi trigger-engineering platform and key therapeutic programs. $NDAQ

$NDAQ structure is broken following today's CPI shock. We are shifting from a buy-the-dip environment to a strict sell-the-rip macro regime. The hot inflation print forced a violent repricing of Fed expectations. Large players are aggressively shedding exposure ahead of tomorrow's heavy data slate (Retail Sales, PPI, TSMC). Institutional order flow is decisively risk-off. Expect algorithmic whipsaws, but the overarching draw on liquidity is lower. Levels: - Invalidation: 30674 - Target 1: 29676 - Target 2: 29492 - Macro Floor: 28750 A final capitulation sweep into the 28750 zone by Friday is the primary expectation. Wait for the sweep. #Nasdaq #Macro